University of Washington

Abacus Bioscience, Inc.

Oncogen

Other

Genetic Systems Corporation

Edward A Clark

Jay Wesley Chaplin

Jeffrey A Ledbetter

Deborah Fuller

Che-Leung Law

Michael J Gale

Amanda Mak

Martha Susan Hayden-Ledbetter

Lynn Massman Rose

Aaron Marshall

Kevin Draves

Elizabeth Ryan

The present invention provides compositions of CD180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.

Compositions and methods for antigen targeting to CD180

Compositions including a CD180 binding ligand and a linked Hepatitis B antigen and their use are disclosed. The Hepatitis B antigen includes Hepatitis B virus pre-S1 and/or pre-S2 region of the HBV envelope protein (HBVpreS1/S2Ag), L-HBsAg, MHBsAg, S-HBsAg, or antigenic fragments or mutants thereof.

Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV PreS1 and/or PreS2, and/or S-HBsAg regions of the HBV envelope protein

The present invention provides compositions of CD 180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.

Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.

Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV core antigen

Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV PreS1 and/or PreS2, and/or s-HBsAg regions of the HBV envelope protein

Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen

The present limiting provides compositions of CD 180 targeting molecules coupled to heterologous antigens, and their use in treating and/or limiting disease.

Disclosed herein are novel CD180 binding molecules, methods for their identification, and methods for their use.

Molecules that bind CD180, compositions and methods of use

The invention provides novel dendritic cell-associated lectin-like (DCAL-1) molecules, compositions and therapeutic methods of use. In one aspect, the invention provides isolated nucleic acid molecules that are capable of remaining hybridized to SEQ ID NO:1 or SEQ ID NO:3, including nucleic acid molecules that encode DCAL-1 polypeptides. In another aspect, the invention provides DCAL-1 polypeptides and portions thereof which are useful to stimulate T cell proliferation. In another aspect, the invention provides antibodies that specifically bind to DCAL-1 which are useful for promoting maturation of dendritic cells and for stimulating an immune response in vivo. In another aspect the invention provides methods of stimulating an immune response in an animal comprising introducing into the animal an anti-DCAL-1 antibody of the invention.

Dendritic cell-associated lectin-like molecules, compositions and methods of use

A new B-cell receptor, Bp50, a 50 kilodalton polypeptide, that functions in B-cell proliferation is described. Ligands such as lymphokines, antibody molecules or the Fv fragments of antibody molecules that bind to Bp50 and augment the proliferation of activated B-cells can be used to regulate B-cell proliferation or differentiation.

Bp 50-specific antibodies and fragments thereof

Ligands and methods for augmenting B-cell proliferation

Methods and compositions are provided for determining a change in status of a multiple sclerosis victim. Particularly, the ratio of helper or suppressor T cell subsets having specific surface markers associated with proliferation is determined, where a particular ratio value is associated with a change in status.

Growing community of inventors

Seattle, WA, United States of America

Edward A Clark